Scleroderma or systemic sclerosis is a debilitating disease that is characterised by fibrosis of multiple organs leading to organ failure and eventually death. There is currently no cure for the disease. We are beginning to find that a newly-discovered class of molecules, called microRNAs, regulate many disease states but its role in scleroderma has not been established. We aim in this study to identify disease-related changes in microRNAs which may subsequently be used as therapeutic targets.
Characterising Protein And Membrane Changes In Age-related Cataract Lenses.
Funder
National Health and Medical Research Council
Funding Amount
$441,624.00
Summary
Cataract is the major cause of blindness worldwide. At present the only treatment for cataract, is surgery. This, however, is associated with complications (e.g. posterior capsule opacification), is expensive (a major component of the Health budget) and cannot keep pace with the incidence of cataract in developing nations. In addition, due to the greying of the community , this problem will be of increasing importance in the future. For prevention, we need to understand why cataract develops.
Novel Approaches To Nanomedicines For Future Therapies
Funder
National Health and Medical Research Council
Funding Amount
$2,414,215.00
Summary
Nanomedicines have the potential to transform healthcare by targeting significant health issues such as Alzheimer’s, diabetes and Parkinson’s diseases that have mainly eluded successful therapeutic solutions. In addition, nanotechnology has the potential to significantly improve the treatment of chronic pain by repurposing analgesic medications for improved effectiveness without significant side effects. I will target these two areas of research during the next five years.
Defining The Changes In Cell Biology Caused By PRESENILIN Truncations Associated With Different Diseases
Funder
National Health and Medical Research Council
Funding Amount
$622,886.00
Summary
Truncations of the PRESENILIN genes in humans can cause two very different diseases: inherited, early onset Alzheimer’s disease (familial Alzheimer's disease) and a skin disease named inherited Acne Inversa. One truncation is also involved in the non-inherited, late onset form of Alzheimer’s disease. Why do these different truncations produce different diseases? Investigating this question will teach us more about the molecular bases of these different diseases. This understanding will be requir ....Truncations of the PRESENILIN genes in humans can cause two very different diseases: inherited, early onset Alzheimer’s disease (familial Alzheimer's disease) and a skin disease named inherited Acne Inversa. One truncation is also involved in the non-inherited, late onset form of Alzheimer’s disease. Why do these different truncations produce different diseases? Investigating this question will teach us more about the molecular bases of these different diseases. This understanding will be required for the development of treatments.Read moreRead less
L1 Retrotransposition: The Missing Link Between Genetics And Environmental Factors In Parkinson's Disease ?
Funder
National Health and Medical Research Council
Funding Amount
$604,644.00
Summary
The study proposed here focuses on understanding the role of specific mobile DNA sequences in the interaction between environmental and genetic risk factors causing Parkinson’s disease (PD) leading to dementia. The project proposes identification of mobile DNA induced mutations in post-mortem human PD patient brain samples. The significance and mechanisms of mobile DNA induced mutations will be then tested in a PD mouse model.
Functional Assessment Of Bioenergetic Defects In Hereditary Spastic Paraplegia
Funder
National Health and Medical Research Council
Funding Amount
$113,322.00
Summary
Hereditary spastic paraplegia (HSP) is a degenerative, hereditary disorder which affects the legs. Currently there are no treatments that target the disease process. We seek to identify the genes responsible for this condition in a group of Australian patients. Cell samples obtained from these patients will be tested for energy defects. We hope to improve our understanding of the underlying disease processes in order to find new ways to prevent, treat and cure this condition.
Developing Species-specific, Structure-targeting Peptides As A Novel Class Of Antibiotics
Funder
National Health and Medical Research Council
Funding Amount
$607,967.00
Summary
Multidrug, antibiotic resistance is a serious global threat. It is a real possibility that in the absence of new antibiotics, common infections could soon become untreatable. This project will develop a novel class of antibiotics that target the core structures of essential bacterial proteins. The successful outcome of this work will also aid the development of specific peptide-based inhibitors for numerous additional diseases, including viral and fungal infections and cancer.
How Does Fra-1 Regulate The Invasive Properties Of Tumour Cells?
Funder
National Health and Medical Research Council
Funding Amount
$468,119.00
Summary
Most cancer deaths occur when tumours spread and destroy vital body functions. The invasion of tumour cells into surrounding tissue is a critical step during the spread of cancer. This project aims to unravel the molecular mechanisms that control the ability of tumour cells to invade into surrounding tissue and subsequently spread to other sites in the body. We expect to identify potential targets to better diagnose and treat the spread of cancer.
Discovery Of Novel Neurodegeneration Genes Via Next-generation Sequencing Technologies And High-throughput Cellular Assays
Funder
National Health and Medical Research Council
Funding Amount
$715,144.00
Summary
My research program aims to discover genes that are mutated in dementia, by identifying gene variants present in patients and absent in healthy people, and examining how these variants affect the function of cells. Identifying new dementia genes will reveal the biological processes that lead to brain cell death. Knowledge of these processes is crucial for the development of new treatments for the many people affected worldwide with dementia.